重大资产重组！刚刚公告，明日复牌！

Core Viewpoint - The article discusses the recent strategic move by Xiangrikui to enter the semiconductor industry through acquisitions, highlighting a trend among A-share companies to diversify into this sector [1][2][4]. Group 1: Company Overview - Xiangrikui plans to acquire 100% equity of Xipu Materials and 40% equity of Beid Pharmaceutical through a combination of share issuance and cash payment, marking a significant asset restructuring [1][2]. - The company, primarily focused on pharmaceuticals, aims to expand into high-end semiconductor materials, which include high-purity electronic gases and silicon-based precursors [3][4]. Group 2: Financial Performance - For the full year of 2024, Xiangrikui reported revenue of 330 million yuan, a decrease of 2.38% year-on-year, with a net profit attributable to shareholders of 7.83 million yuan, down 64.01% [2]. - In the first half of 2025, the company’s revenue was 144 million yuan, reflecting an 8.33% decline compared to the same period last year, with a net profit of 1.16 million yuan, down 35.68% [2][3]. Group 3: Market Context - Since the implementation of the "Six Merger Rules" by the CSRC in September last year, there has been a surge in A-share companies pursuing mergers and acquisitions, particularly in the semiconductor sector [4][5]. - Other companies, such as Kaipu Cloud and Tongye Technology, have also announced plans to acquire stakes in semiconductor-related firms, indicating a broader trend of diversification into this industry [4][5][6].